Three molecules, two listings
CJC-1295 without DAC, also called modified GRF (1-29), keeps the first 29 residues of growth-hormone-releasing hormone with four substitutions (D-alanine at position 2, glutamine at 8, alanine at 15, leucine at 27) and a C-terminal amide. Tesamorelin keeps all 44 residues of the same parent and adds a trans-3-hexenoyl group to the N-terminus. Ipamorelin is unrelated in structure: a five-residue chain built largely from non-protein residues. The CJC-1295 + Ipamorelin 10mg listing combines the first and third in one vial; the Tesamorelin 10mg listing is the second on its own.
| Property | CJC-1295 (no DAC) | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Residue count | 29 | 5 | 44, plus an N-terminal acyl group |
| Ends | Free N-terminus; C-terminal amide | C-terminal amide | trans-3-Hexenoyl N-terminus; C-terminal amide |
| Non-standard residues | D-alanine at position 2 | Aib, D-2-naphthylalanine, D-phenylalanine | None in the chain |
| Molecular formula | C152H252N44O42 | C38H49N9O5 | C221H366N72O67S |
| CAS registry number | 863288-34-0 | 170851-70-4 | 218949-48-5 |
| Theoretical average mass | 3,367.9 g/mol | 711.9 g/mol | about 5,136 g/mol |
| Theoretical monoisotopic mass | approximately 3,365.9 | approximately 711.4 | approximately 5,132.7 |
| Ions a mass spectrum typically shows | Multiply charged: near m/z 1,123.0 (3+), 842.5 (4+), 674.2 (5+) | near m/z 712.4 (1+) and 356.7 (2+) | Multiply charged: near m/z 1,284.2 (4+), 1,027.6 (5+), 856.5 (6+) |
| Sulfur in the formula | None (leucine replaces the parent's methionine at 27) | None | One (methionine at position 27) |
| Physical form supplied | Lyophilized solid | ||
Formulas and CAS numbers are the ones published on the single-compound listings (CJC-1295 (No DAC) 5mg, Ipamorelin 10mg, Tesamorelin 10mg); the ions are calculated from them. The blend listing states a total of 10 mg; the report for a blend lot should state the measured content of each component.
A blend is two documentation problems in one vial
A single-compound certificate assumes one intended peak. A blend breaks that assumption, as set out in what a blend COA has to show. For this pair, that means:
- Two identity results. One mass near 3,368 g/mol and one near 712 g/mol, or two retention-time matches against two named reference standards. One identity line cannot cover both.
- Purity per component, or a stated composition. A single blended percentage has no interpretation when two peaks are supposed to be there.
- Net content per component. The measured mg of each, next to the labeled total, so the ratio in the vial can be read.
- A chromatogram with both intended peaks assigned. With two expected main peaks, an unlabelled trace is close to unreadable.
- A different impurity picture for each component. CJC-1295 (no DAC) is a 29-residue synthesis, so near-eluting deletion sequences are expected beside its peak. Ipamorelin's three non-protein residues mean your own mass arithmetic will disagree with the certificate, as explained in Ipamorelin: unnatural residues and why the mass looks wrong. Neither formula contains sulfur, so a methionine oxidation peak is not expected from either.
Tesamorelin: one long chain and the group on its end
- Length sets the impurity profile. Forty-three couplings leave many places for a deletion, so a broader family of near-eluting peaks is expected and the chromatogram matters more than the number.
- The acyl group has to be confirmed. The trans-3-hexenoyl group adds roughly 96 mass units. A chain that never received it is a legitimate peptide that is not this product, and a mass result rules it out directly. See Tesamorelin: a 44-residue chain and the group on its end.
- One methionine. An oxidised species 16 units heavier is resolvable by mass spectrometry and tends to elute slightly earlier.
- An envelope, not a single ion. A molecule this size appears as several multiply charged ions; the report should state the deconvoluted mass and whether it is monoisotopic or average.
What each certificate of analysis must show
| Report section | For a CJC-1295 + Ipamorelin blend lot | For a Tesamorelin lot |
|---|---|---|
| Identity | Two results: a mass in agreement with 3,367.9 g/mol for CJC-1295 (no DAC) and with 711.9 g/mol for Ipamorelin, with charge states listed, or HPLC-RTM against two named reference standards | Deconvoluted mass in agreement with about 5,136 g/mol within tolerance, with the charge states listed, or HPLC-RTM against a named tesamorelin reference standard |
| Chromatographic purity | Purity for each component, or a stated composition, with both intended peaks assigned on the published chromatogram | Main-peak area as a percentage of total integrated area, with the chromatogram published; expect a family of near-eluting deletion peaks and check for a +16 oxidation peak |
| Net content | Measured mg of each component, and their sum compared with the labeled 10 mg total | Measured mg of peptide in the vial, stated next to the labeled strength |
| Endotoxin | Where tested: the method (LAL, with the USP <85> reference if claimed), the result with its units (EU per mL, per mg or per vial), and the limit it was compared against. | |
| Heavy metals | Where tested: the elements in the panel, the method, and a result or "none detected" against a stated reporting limit. | |
| Method fields | Column, mobile phase or gradient, detection wavelength, and reporting limit. A percentage with no method attached is not a result. | |
| Record fields | Material name, labeled strength, lot identifier matching the vial label, test date, certificate or accession number, and the issuing laboratory with its verification route. | |
Endotoxin and heavy-metal screens are only part of a report when the laboratory ran them. If a line is not on the certificate, that test was not performed on that lot; it has not been passed. The endotoxin testing guide explains what a LAL result and a USP <85> pass mean, and net peptide content explains why the measured mg can differ from the label.
How to read our reports for these listings
Our current reports come from three laboratories. Freedom Diagnostics reports give purity by HPLC-UV, identity by LC-MS, net content in mg, and an endotoxin result where one is listed; each carries an accession number and a search code for the laboratory's lookup page. ILS Laboratories reports give purity by HPLC, identity by retention-time match against a reference standard, net peptide content, and the screens run on that lot. Janoshik Analytical reports carry the laboratory's own verification key. Verify a lab report walks through each lookup.
- Tesamorelin 10mg: lot TS-2502B, 99.84% by HPLC-UV, identity confirmed by LC-MS, net content 11.04 mg, endotoxin pass (LAL, USP <85>, 2 replicates), reported Oct 15, 2026 by Freedom Diagnostics, accession 2610140675.
- Ipamorelin 10mg: lot IPA-2510-A, 99.83% by HPLC-UV, identity confirmed by LC-MS, net content 10.67 mg, reported Nov 1, 2026 by Freedom Diagnostics, accession 2610284027. This is a single-compound record and does not describe a blend lot.
- CJC-1295 (No DAC) 5mg: no exact-lot report is published as of this page's date.
- CJC-1295 + Ipamorelin 10mg: listed in November 2026. Each lot is third-party tested, and the report is posted on the product page and in the COA library when it is back. As of November 10, 2026 no blend report is published yet.
Common questions
How does a CJC-1295 + Ipamorelin blend report differ from a Tesamorelin report?
The blend report has to identify two compounds, CJC-1295 without DAC (C152H252N44O42, 3,367.9 g/mol) and Ipamorelin (C38H49N9O5, 711.9 g/mol), and give purity or composition and net content for each. A Tesamorelin report describes one 44-residue chain (C221H366N72O67S, about 5,136 g/mol) and has to confirm its N-terminal hexenoyl group.
What masses should each report state?
CJC-1295 (no DAC): about 3,365.9 monoisotopic or 3,367.9 g/mol average, usually seen as multiply charged ions near m/z 1,123.0, 842.5 and 674.2. Ipamorelin: about 711.4 or 711.9 g/mol, near m/z 712.4 and 356.7. Tesamorelin: about 5,132.7 or 5,136 g/mol, near m/z 1,284.2, 1,027.6 and 856.5.
Why can one purity figure not describe a two-peptide blend?
Purity is the main peak as a share of everything detected. In a blend two peaks are supposed to be there, so one figure would count one component as an impurity of the other. The report needs purity or composition per component, both peaks assigned on the chromatogram, and net content for each.
Which of these lots are documented on this site?
Tesamorelin 10mg lot TS-2502B (99.84%, Freedom Diagnostics, Oct 15, 2026) and Ipamorelin 10mg lot IPA-2510-A (99.83%, Nov 1, 2026) have published reports. The CJC-1295 + Ipamorelin 10mg blend was listed in November 2026; its lot report is posted on the product page and in the COA library when it is back.